- Home
- MREO vs CCIF Comparison
MREO vs CCIF Comparison
Compare MREO & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MREO | CCIF |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 48.7M |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MREO | CCIF |
|---|---|---|
| Price | $0.30 | $2.16 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $1.97 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 146.6K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.97 |
| 52 Week High | $2.37 | $5.46 |
Technical Indicators
Market Signals| Indicator | MREO | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 37.68 |
| Support Level | $0.26 | N/A |
| Resistance Level | $0.35 | $2.91 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.85 | 44.12 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.